A trial comparing nucleoside monotherapy with sequential therapy with 3 drugs in HIV-infected patients

B Roca; P Olmos; C Mínguez; A Arnedo; J Usó; C Teruel; M Segarra; A Sáez-Royuela; E Simón

doi:10.1080/00365549850160792

A trial comparing nucleoside monotherapy with sequential therapy with 3 drugs in HIV-infected patients

Scand J Infect Dis. 1998;30(4):426-8. doi: 10.1080/00365549850160792.

Authors

B Roca¹, P Olmos, C Mínguez, A Arnedo, J Usó, C Teruel, M Segarra, A Sáez-Royuela, E Simón

Affiliation

¹ Medicine Department, Hospital General, Castellón, Spain.

PMID: 9817530
DOI: 10.1080/00365549850160792

Abstract

53 HIV-positive patients, 66% of them zidovudine-experienced, were randomized to receive monotherapy with zidovudine or sequential therapy with zidovudine, didanosine and zalcitabine. Clinical end points, CD4 cell count change, and analysis abnormalities showed better results with sequential therapy.

Publication types

Clinical Trial
Randomized Controlled Trial

MeSH terms

Adult
Anti-HIV Agents / therapeutic use
CD4 Lymphocyte Count
Didanosine / therapeutic use*
Drug Therapy, Combination
Female
HIV Infections / drug therapy*
Humans
Male
Reverse Transcriptase Inhibitors / therapeutic use*
Treatment Outcome
Zalcitabine / therapeutic use*
Zidovudine / therapeutic use*

Substances

Anti-HIV Agents
Reverse Transcriptase Inhibitors
Zidovudine
Zalcitabine
Didanosine